SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-24-100792
Filing Date
2024-04-18
Accepted
2024-04-18 16:13:55
Documents
5
Period of Report
2024-05-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A d773782ddef14a.htm DEF 14A 369040
2 GRAPHIC g773782dsp1.jpg GRAPHIC 2596
3 GRAPHIC g773782dsp1a.jpg GRAPHIC 4109
4 GRAPHIC g773782dsp1b3.jpg GRAPHIC 778
5 GRAPHIC g773782g02a01.jpg GRAPHIC 37729
  Complete submission text file 0001193125-24-100792.txt   433009
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39536 | Film No.: 24854453
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)